CN107698593A - 作为fgfr抑制剂的杂环化合物 - Google Patents

作为fgfr抑制剂的杂环化合物 Download PDF

Info

Publication number
CN107698593A
CN107698593A CN201610647295.0A CN201610647295A CN107698593A CN 107698593 A CN107698593 A CN 107698593A CN 201610647295 A CN201610647295 A CN 201610647295A CN 107698593 A CN107698593 A CN 107698593A
Authority
CN
China
Prior art keywords
alkyl
ring
independently selected
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610647295.0A
Other languages
English (en)
Chinese (zh)
Inventor
孔祥龙
周超
陈向阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Innocare Pharma Tech Co ltd
Original Assignee
Nanjing Tian Jian Hua Medicine Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Tian Jian Hua Medicine Technology Co Ltd filed Critical Nanjing Tian Jian Hua Medicine Technology Co Ltd
Priority to CN201610647295.0A priority Critical patent/CN107698593A/zh
Priority to PCT/CN2017/094620 priority patent/WO2018028438A1/zh
Priority to US16/324,189 priority patent/US10752631B2/en
Priority to CN201780045675.XA priority patent/CN109715626B/zh
Priority to JP2019529309A priority patent/JP6959663B2/ja
Priority to EP17838568.8A priority patent/EP3498706A4/en
Priority to CA3032921A priority patent/CA3032921A1/en
Priority to KR1020197006637A priority patent/KR20190035870A/ko
Publication of CN107698593A publication Critical patent/CN107698593A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201610647295.0A 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物 Pending CN107698593A (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201610647295.0A CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物
PCT/CN2017/094620 WO2018028438A1 (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物
US16/324,189 US10752631B2 (en) 2016-08-09 2017-07-27 Heterocyclic compounds as FGFR inhibitors
CN201780045675.XA CN109715626B (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物
JP2019529309A JP6959663B2 (ja) 2016-08-09 2017-07-27 Ｆｇｆｒ阻害剤としての複素環化合物
EP17838568.8A EP3498706A4 (en) 2016-08-09 2017-07-27 HETEROCYCLIC COMPOUND AS FGFR INHIBITOR
CA3032921A CA3032921A1 (en) 2016-08-09 2017-07-27 Heterocyclic compounds as fgfr inhibitors
KR1020197006637A KR20190035870A (ko) 2016-08-09 2017-07-27 Fgfr 저해제로서 헤테로시클릭 화합물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610647295.0A CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物

Publications (1)

Publication Number Publication Date
CN107698593A true CN107698593A (zh) 2018-02-16

Family

ID=61162708

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610647295.0A Pending CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物
CN201780045675.XA Active CN109715626B (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780045675.XA Active CN109715626B (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物

Country Status (7)

Country Link
US (1) US10752631B2 (US07794700-20100914-C00152.png)
EP (1) EP3498706A4 (US07794700-20100914-C00152.png)
JP (1) JP6959663B2 (US07794700-20100914-C00152.png)
KR (1) KR20190035870A (US07794700-20100914-C00152.png)
CN (2) CN107698593A (US07794700-20100914-C00152.png)
CA (1) CA3032921A1 (US07794700-20100914-C00152.png)
WO (1) WO2018028438A1 (US07794700-20100914-C00152.png)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480109A (zh) * 2020-11-16 2021-03-12 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
CN114127051A (zh) * 2019-05-17 2022-03-01 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
CN114853739A (zh) * 2021-02-03 2022-08-05 药雅科技(上海)有限公司 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途
CN115043832A (zh) * 2021-03-08 2022-09-13 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
CN116096707A (zh) * 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333779A (zh) 2017-05-08 2023-09-01 美商磨石生物公司 阿爾法病毒新抗原載體
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022152090A1 (en) * 2021-01-12 2022-07-21 Beijing Innocare Pharma Tech Co., Ltd. Process for preparing (s)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl) ethynyl)-5-(methylamino)-1h-pyrazole-4-carboxamide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
CN104341425A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
CN104341388A (zh) * 2013-10-16 2015-02-11 上海润诺生物科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
US20160031888A1 (en) * 2013-03-13 2016-02-04 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EP3023100A1 (en) * 2013-07-18 2016-05-25 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819398T3 (es) * 2013-07-18 2021-04-15 Taiho Pharmaceutical Co Ltd Agente terapéutico para el cáncer resistente al inhibidor de FGFR
JP6445684B2 (ja) * 2014-08-19 2018-12-26 シャンハイ ハイヘ ファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｈｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｆｇｆｒキナーゼ阻害剤としてのインダゾール系化合物およびその製造と使用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
US20160031888A1 (en) * 2013-03-13 2016-02-04 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EP3023100A1 (en) * 2013-07-18 2016-05-25 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor
US20160193210A1 (en) * 2013-07-18 2016-07-07 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor
CN104341425A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
CN104341388A (zh) * 2013-10-16 2015-02-11 上海润诺生物科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张媛等: "以c-Met为肿瘤治疗靶点的受体酪氨酸激酶抑制剂的研究进展", 《中国药科大学学报》 *
朱贺敏等: "癌症靶标Aurora A激酶结构、功能与抑制剂研究进展", 《中国药学杂志》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127051A (zh) * 2019-05-17 2022-03-01 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
CN116096707A (zh) * 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
CN112480109A (zh) * 2020-11-16 2021-03-12 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
CN114853739A (zh) * 2021-02-03 2022-08-05 药雅科技(上海)有限公司 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途
CN114853739B (zh) * 2021-02-03 2023-09-22 药雅科技(上海)有限公司 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途
CN115043832A (zh) * 2021-03-08 2022-09-13 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
CN115043832B (zh) * 2021-03-08 2023-08-22 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物

Also Published As

Publication number Publication date
CA3032921A1 (en) 2018-02-15
CN109715626A (zh) 2019-05-03
EP3498706A4 (en) 2020-02-26
EP3498706A1 (en) 2019-06-19
CN109715626B (zh) 2022-04-26
KR20190035870A (ko) 2019-04-03
US20190177333A1 (en) 2019-06-13
JP2019524883A (ja) 2019-09-05
US10752631B2 (en) 2020-08-25
WO2018028438A1 (zh) 2018-02-15
JP6959663B2 (ja) 2021-11-02

Similar Documents

Publication Publication Date Title
CN107698593A (zh) 作为fgfr抑制剂的杂环化合物
JP6919922B2 (ja) Ｆｇｆｒ４阻害剤、その製造方法と薬学的な応用
CN107840842A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
CN107619388A (zh) 作为fgfr抑制剂的杂环化合物
CN109956957A (zh) 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
CN107021963A (zh) 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
CN113518779B (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN110691775B (zh) 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
WO2019223766A1 (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
WO2021197250A1 (zh) 作为转染期间重排激酶抑制剂的新的化合物
WO2023061434A1 (zh) 一种三环化合物的用途
JP2006510727A (ja) キナーゼモジュレーター
CN114605391B (zh) 喹喔啉类衍生物及其制备方法和应用
CN113072550B (zh) 一种高选择性成纤维细胞生长因子受体抑制剂和应用
CN110526898A (zh) 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
CN101605794A (zh) 氮杂苯并呋喃基化合物及使用方法
CN114763360A (zh) 手性大环化合物作为蛋白激酶抑制剂及其用途
CN111138459B (zh) Fgfr4抑制剂的光学异构体及其应用
CN110272415A (zh) 3,4-二氢吡啶并[4,3-d]嘧啶类衍生物及其制备方法和用途
CN103923066A (zh) 多靶点抗肿瘤化合物及其制备方法和应用
CN114957242A (zh) 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用
CN116693551A (zh) 二氢吡唑氮杂卓类化合物、含其的药物组合物及其在抗肿瘤中的应用
CN104211687B (zh) 杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
CN116535423A (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180612

Address after: 102206 Building 8, No. 8, life Park Road, Changping District science and Technology Park, Beijing

Applicant after: BEIJING INNOCARE PHARMA TECH Co.,Ltd.

Address before: 211100 south building, 5 building, 568 dragon sleeping Avenue, Science Park, Jiangning District, Nanjing, Jiangsu.

Applicant before: NANJING INNOCARE PHARMA TECH Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20181011

Address after: 510130 Guangzhou 899, Guangdong, Guangzhou, China, nine Jianshe Road, 333 knowledge city.

Applicant after: NANJING INNOCARE PHARMA TECH Co.,Ltd.

Address before: 102206 Building 8, No. 8, life Park Road, Changping District science and Technology Park, Beijing

Applicant before: BEIJING INNOCARE PHARMA TECH Co.,Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180216